{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T01:08:48Z","timestamp":1793063328434,"version":"4.5.0"},"reference-count":24,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatology"],"abstract":"<jats:p>Introduction: Alopecia areata (AA) is an autoimmune disorder with a higher prevalence in pediatric patients than adults, but treatment options remain limited. Baricitinib, a Janus kinase (JAK)-1\/2 inhibitor, has shown efficacy in adults with severe AA, yet data on its use in pediatric patients are limited. Methods: This study included pediatric patients (ages 2\u201318) with severe AA (Severity of Alopecia Tool [SALT] \u226550) treated with baricitinib for at least 3 months between January 2023 and October 2024. Demographics, SALT scores before and after treatment, and adverse events were collected. Results: Thirty-three patients were included, with a mean age of 9.93 years and average disease duration of 23.44 months. Sixteen patients received 2 mg and 17 received 4 mg of baricitinib. At baseline, 54.5% had a SALT score above 90. After treatment, 45.5% of patients had a 50% reduction in their SALT score. The average treatment duration was 6.5 months. Adverse events included elevated ALT (n = 1), acne (n = 1), and upper respiratory infection (n = 1), with no serious adverse events. Conclusion: Baricitinib demonstrated clinical efficacy and good tolerance in pediatric patients with severe AA.<\/jats:p>","DOI":"10.1159\/000547786","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T16:02:35Z","timestamp":1754582555000},"page":"1-6","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and Safety of Baricitinib in the Treatment of Severe Alopecia Areata in Pediatric Patients: Data from Real-Clinical Practice"],"prefix":"10.1159","author":[{"given":"Dandan","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shufen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongdi","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijian","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2025,8,7]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.08.032"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.0351"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.10.032"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12315"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2016.1188076"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.04.077"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15489"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2147\/ccid.S53985"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.12941"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/0010-440x(91)90045-e"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.2003.01340.x"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5154.135525"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10714.x"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110343"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-01044-5"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2015.02.015"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15845"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.12.033"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.16123"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.2002.01357.x"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-023-00764-w"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2324832"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.05.050"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad253"}],"container-title":["Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000547786","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T16:00:45Z","timestamp":1757952045000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000547786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,7]]},"references-count":24,"URL":"https:\/\/doi.org\/10.1159\/000547786","archive":["Portico"],"relation":{},"ISSN":["1018-8665","1421-9832"],"issn-type":[{"value":"1018-8665","type":"print"},{"value":"1421-9832","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,7]]}}}